Real-world effectiveness of extra-fine formulations in Denmark

Study identification

• EU PAS number:
  EUPAS9105
• Study ID:
  26282
• Official title and acronym:
  Real-world effectiveness of extra-fine formulations in Denmark
• DARWIN EU® study:
  No
• Study countries:
  Denmark
• Study description:
  A retrospective effectiveness analysis comparing extra-fine inhaled corticosteroid formulations with non extra-fine inhaled corticosteroid formulations in the real-world management of patients with asthma in Denmark
• Study status:
  Ongoing

Research institutions and networks

Institutions

Observational & Pragmatic Research Institute Pte (OPRI)

United Kingdom

Forskningsenheden for Almen Praksis IST, Syddansk Universitet

Study timelines

Date when funding contract was signed

Planned: 10/12/2013

Actual: 07/05/2014

Study start date

Planned: 02/04/2014

Actual: 30/06/2014

Data analysis start date

Planned: 14/07/2014

Actual: 19/08/2014

Date of interim report, if expected

Planned: 10/12/2014

Actual: 26/09/2014

Date of final study report

Planned: 30/06/2015

Sources of funding

Non-for-profit organisation (e.g. charity)

Pharmaceutical company and other private sector 

More details on funding

Teva, RiRL

Regulatory

• Was the study required by a regulatory body?:
  No
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable